Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Zoetis
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Tom_Weaver
|
| gptkbp:focus |
gptkb:veterinary_medicine
monoclonal antibodies |
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Tom_Weaver
|
| https://www.w3.org/2000/01/rdf-schema#label |
PetMedix
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:location |
gptkb:Cambridge,_United_Kingdom
|
| gptkbp:product |
species-specific antibody therapeutics
|
| gptkbp:targetMarket |
companion animals
|
| gptkbp:website |
https://www.petmedix.com/
|
| gptkbp:bfsParent |
gptkb:Wellcome_Trust_Sanger_Institute
|
| gptkbp:bfsLayer |
5
|